33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 clinical and biomarker results
    Meeting Abstract

    Liu, J.; O'Malley, D.; Van Nieuwenhuysen, E.; Moore, K.; Hamilton, E.; Yeku, O.; Bouberhan, S.; Hou, J.; Schröder, D.; Wang, B.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour brca1/2 mutation: Results from the DUO-O/ENGOT-OV46/AGO-OVAR 23/GOG-3025 trial
    Meeting Abstract

    Marth, C.; Park-Simon, T. W.; Aghajanian, C.; Reuss, A.; Nishio, S.; Lim, M. C.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Sabatier, R.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Prognosis of surgically staged FIGO IA uterine carcinosarcoma without myometrial invasion: A multicenter international retrospective cohort study
    Meeting Abstract

    Cucinella, G.; Zammarrelli, W. A.; Nasioudis, D.; Capasso, I.; Berretta, R.; Scollo, P.; Francesco, R.; Baiocchi, G.; Barresi, G.; Basilio, P.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy
    Meeting Abstract

    Grisham, R.; Aghajanian, C.; Van Nieuwenhuysen, E.; Rodrigues, M.; Ring, K.; Santin, A.; Colombo, N.; Prendergast, E.; Thaker, P.; Moore, K.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Near-infrared fluorescence assessment of myocutnaeous flap microperfusion for gynecologic reconstruction (forefront): A prospective, non-randomized trial (NCT05071976)
    Meeting Abstract

    Manning-Geist, B.; Jamner, A.; Leitao, M. M.; Afonso, A.; Mueller, J. J.; Shahzad, F.; Coriddi, M.; Dayan, J.; Burke, E.; Wei, I.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Oncologic outcomes of minimally invasive surgery versus laparotomy for the treatment of apparent uterine-confined clear cell carcinoma
    Meeting Abstract

    Dagher, C.; Sassine, D.; Abu-Rustum, N. R.; Mueller, J. J.; Borach, V.; Zivanovic, O.; Sonoda, Y.; Leitao, M. M.
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Survival associated with extent of radical hysterectomy in early-stage cervical cancer: A sub-analysis of the SCCAN collaborative study
    Meeting Abstract

    Bizzarri, N.; Querleu, D.; Dostalek, L.; Van Lonkhuijzen, L. R.; Giannarelli, D.; Lopez, A.; Salehi, S.; Ayhan, A.; Kim, S. K.; Ortiz, D. I.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Oncologic outcomes of sentinel lymph node mapping versus lymph node dissection in staging of apparent uterine-confined clear cell carcinoma
    Meeting Abstract

    Dagher, C.; Sassine, D.; Abu-Rustum, N. R.; Mueller, J. J.; Borach, V.; Zivanovic, O.; Sonoda, Y.; Friedman, C.; Leitao, M. M.
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Initial Efficacy and Safety Results from ENGOT-Ov60/GOG-3052/ramp 201: A phase 2 study of avutometinib (vs-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Banerjee, S. N.; Ring, K. L.; Van Niewenhuysen, E.; Fabbro, M.; Aghajanian, C.; Oaknin, A.; Colombo, N.; Santin, A. D.; Clamp, A. R.; Moore, K. N.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • DB-1303, a HER2-targeting ADC, for patients with advanced/metastatic endometrial cancer: Preliminary clinical results from an ongoing phase 1/2A Trial (NCT05150691)
    Meeting Abstract

    Moore, K.; Makker, V.; Yeku, O.; Pothuri, B.; Growden, W.; Hamilton, E.; Musa, F.; Wang, L.; Li, X.; Godbee, N.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save